Pancreatic Cancer Clinical Trials

Showing 1-1 of 1 items
1.
  • M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
  • People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called M402. It is made from heparin, which is a well known blood thinner. Blood thinners have been shown in prior animal and human studies to have anti-cancer effects. M402 has been re-engineered from heparin to have much lower blood thinning activity while keeping the anti-tumor activity. The investigators are testing whether M402 administered in combination with nab-paclitaxel and gemcitabine may be more effective than nab-paclitaxel and gemcitabine.
  • Diagnoses: Gastrointestinal Malignancies, Pancreatic Cancer
  • Status: Recruiting
Showing 1-1 of 1 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms